You are here

Shire

Shire CEO: Hemophilia will remain a core business

BioPharma Dive

Mon, 12/11/17 - 09:49 am

Flemming Ornskov

The Only 3 Big Pharma Companies Growing Market Share

Motley Fool

Tue, 11/7/17 - 09:59 am

Bristol-Myers Squibb

Mydayis sales shine as Shire still looks to divest neuro

BioPharma Dive

Sat, 10/28/17 - 11:07 pm

Under breakup pressure, Shire cheers grumpy investors with Q3 earnings beat

Fierce Pharma

Fri, 10/27/17 - 02:45 pm

What's next for biopharma Q3 earnings

Biopharma Dive

Sat, 10/21/17 - 09:50 pm

Bristol-Myers Squibb

Gilead Sciences

Activist hedge fund angles for Shire breakup to revive struggling shares

Fierce Pharma

Mon, 10/16/17 - 09:22 pm

Shire says trial shows new HAE drug significantly reduces attacks

Reuters

Tue, 09/12/17 - 10:15 am

clinical trials

hereditary angiodema

Allergan-Restasis Patent Battle Could Test Lawmakers' Resolve

NY Shock Exchange

Wed, 09/6/17 - 09:11 am

Teva Pharmaceutical

Shire defends record as UBS cuts price target on staff satisfaction reviews

Reuters

Wed, 08/30/17 - 11:43 pm

Shire announces availability of MYDAYIS(TM) for ADHD treatment in the U.S.

Seeking Alpha

Mon, 08/28/17 - 10:00 am

Under fire from Shire, Roche grabs the VIP lane for top drug prospect emicizumab

Endpoints

Thu, 08/24/17 - 09:53 am

Shire hints at ADHD spinoff, but could someone step in and buy the neuro franchise?

Fierce Pharma

Thu, 08/3/17 - 06:39 pm

Shire plots an ADHD public spinoff as CEO Ornskov completes a top-to-bottom overhaul

Endpoints

Thu, 08/3/17 - 11:01 am

Flemming Ornskov

Shire increasingly vulnerable to takeover attempts by big pharma companies

GoInPharma

Wed, 08/2/17 - 09:22 am

5 Pharma & Biotech Stocks That Could Be Big Winners in Q2 Earnings

Yahoo/Zacks.com

Thu, 07/13/17 - 09:49 am

Gilead Sciences

Shire blasts rival Roche for its “misleading” case for hemophilia trailblazer emicizumab

Motley Fool

Sun, 07/9/17 - 07:39 pm

Rare-Disease Drugmakers Join in Worries Over GOP Health Overhaul

Bloomberg

Fri, 07/7/17 - 10:31 am

healthcare reform

Jazz Pharmaceuticals

Vertex Pharmaceuticals

Shire will cut U.S. locations and move HQ in consolidation push

Fierce Biotech

Wed, 07/5/17 - 11:23 am

Shire’s Ornskov dictates another big revamp, with R&D/HQ moving into Cambridge

Endpoints

Sat, 07/1/17 - 09:25 am

Flemming Ornskov

Pfizer Fueling Growth Of Competitors' Pipelines

Forbes

Tue, 06/27/17 - 10:02 am

Clovis Oncology

Puma Biotechnology

Pages